Molecular simulations have boosted knowledge of CRISPR/Cas9: A Review by Ray, Angana & Di Felice, Rosa
 1 
Molecular simulations have boosted knowledge of CRISPR/Cas9: A Review  
 
Angana Ray1* and Rosa Di Felice1,2,3* 
 
1Department of Physics and Astronomy, University of Southern California, Los Angeles, CA 
90089, USA 
2Department of Biological Sciences, Quantitative and Computational Biology sector, University 
of Southern California, Los Angeles, CA 90089, USA 
3CNR Institute of Nanosciences, Via Campi 213/A, 41125 Modena, Italy 
 
Abstract 
Genome editing allows scientists to change an organism’s DNA. One promising genome 
editing protocol, already validated in living organisms, is based on clustered regularly interspaced 
short palindromic repeats (CRISPR)/Cas protein-nucleic acid complexes. When the CRISPR/Cas 
approach was first demonstrated in 2012, its advantages with respect to previously available 
techniques, such as zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases 
(TALENs), immediately got attention and the method has seen a surge of experimental and 
computational investigations since then. However, the molecular mechanisms involved in target 
DNA recognition and cleavage are still not completely resolved and need further attention. The 
large size and complex nature of CRISPR/Cas9 complexes has been a challenge for computational 
studies, but some seed results exist and are illuminating on the cleavage activity. In this short 
review, we present recent progress in studying CRISPR/Cas9 systems by molecular dynamics 
simulations with coarse-grained and atomistic descriptions, including enhanced sampling. 
 
Introduction 
During the Second International Summit on Human Genome Editing in Hong Kong in 
November 2018, He Jiankui of the Southern University of Science and Technology (SUST) in 
Shenzhen, China, announced that a set of twin girls were brought into the world after applying the 
CRISPR/Cas9 genome editing technique. The girls were born to an HIV-negative mother and an 
HIV-positive father. He Jiankui reported that the mother was impregnated with embryos modified 
by CRISPR/Cas9 facilitated knockdown of chemokine receptor (CCR5), making the embryos 
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resistant to HIV infection (1). This is a clear evidence of the huge potential impact of genome 
editing in human life. 
Nearly two decades ago, the paper titled ‘Initial sequencing and analysis of the human 
genome’ (2) was published and considered to be a major milestone in the international Human 
Genome Project. Ever since, human genetics has become the focus of biomedical research and 
therapeutics. By definition, a genome is an organism’s complete set of DNA, which is composed 
of DNA bases in stacked pairs. The process of accurately changing the DNA bases at 
predetermined locations is genome editing. The ability to intentionally precisely modify the 
genetic code is highly valuable and it is the objective of intense research efforts. There currently 
exist different plausible molecular techniques, of which CRISPR/Cas is the most promising one.  
In this short review, after tracing the history of the CRISPR/Cas technique and describing 
the structure of the molecular complexes, we focus on computational studies of the system, which 
nicely complement experimental work in the field. Cas is the short name for “CRISPR-associated 
protein”; there are different such proteins and Cas9, CRISPR-associated protein 9, is one of them.  
 
Historical Background 
 
Genome editing techniques like transcription activator-like effector nucleases (TALENs), 
zinc-finger nucleases (ZFNs) and CRISPR/Cas have already enabled researchers to make precise 
modifications at the nucleotide level. In ZFNs and TALENs, the DNA sequence is recognized by 
a protein: thus, different protein mutants need to be engineered for different target sequences. In 
CRISPR/Cas, instead, there is no need for lengthy protein engineering, because the target DNA 
sequence is recognized by a complementary RNA sequence bound to an endonuclease protein. 
The CRISPR/Cas method offers a number of other advantages over TALENs and ZFNs: it is easily 
programmable, inexpensive and efficient. The CRISPR/Cas timeline (Figure 1) is intriguing. It 
includes results starting from 1987, when the CRISPR cluster repeats were reported for the first 
time (3). However, it was much later, in August 2012, that Emmanuelle Charpentier, in 
collaboration with Jennifer Doudna at the University of California Berkeley, demonstrated the use 
of CRISPR/Cas9 to target and cleave five specific genomic sites of the gene encoding the green 
fluorescent protein (GFP) (4): they generalized their conclusions to potentially any target DNA 
sequence. Further significant progress was achieved slightly after, in February 2013, when Feng 
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Zhang of the Broad Institute of MIT and Harvard in Cambridge, MA, reported the use of 
CRISPR/Cas9 for editing genomes of cultured mouse cells and human cells (5). In 2014 the first 
crystal structures of CRISPR/Cas9 (6, 7) complexes were made available in the Protein Data Bank. 
CRISPR/Cas is now a very fast-moving field of research, with more than 17000 reports available 
in 2018. 
 
 
Figure 1: CRISPR/Cas timeline until 2015, with focus on the endonuclease Cas9. The red-colored 
boxes highlight the most representative events in the history of CRISPR/Cas. 
 
The Natural Origin of the CRISPR/Cas technique 
 
Viruses have been a common threat to the survival of bacteria and archaea. As a result of 
this battle between predator and prey, an array of countermeasures has been adopted by the host 
organism. The CRISPR system is one such highly adaptive and inheritable bacterial defense 
mechanism (8) (Figure 2). When a bacterium is infected by a virus and overcomes the infection, 
it archives fragments of the viral genome, as a memory of the infection. The viral sequences are 
integrated into the bacterial DNA and intercalated by short repeating elements. The modified 
bacterial DNA is translated into single strands of RNA that, anchored to suitable proteins, scan 
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new infecting viruses, which are immediately neutralized if the previous infection is recognized 
through DNA-RNA complementarity. This CRISPR/Cas technique requires the presence of a set 
of CRISPR-associated (cas) genes (9) and acts in three stages: (i) adaptation, e.g., insertion of new 
spacers in CRISPR locus, (ii) expression, e.g., transcription of CRISPR RNA (crRNA) and (iii) 
interference, e.g., recognition and destruction of target DNA sequences (9, 10). 
 
 
Figure 2: CRISPR/Cas9-mediated acquired immunity in prokaryotes. During the acquisition phase 
(A), cellular invaders such as phage viruses inject nucleic acid sequences into the host cell. After 
infection, novel DNA sequences from the cellular invaders are incorporated into the host CRIPSPR 
locus as spacers (colored circles) flanked by repeat sequences (gray diamonds). As a result, when 
the CRISPR locus is transcribed, the pre‐CRISPR RNAs (crRNAs) encode the newly acquired 
protospacer sequences. The pre‐crRNA is cleaved to produce individual crRNAs that will associate 
with Cas proteins. The Cas protein utilizes the crRNAs as guides to silence foreign DNA that 
matches the crRNA sequence (B, interference phase). As a result, the second time a bacterium 
encounters the same foreign DNA, the crRNA/Cas9 complex is able to identify and silence the 
DNA. From Ref (11) with permission. 
 
CRISPR/Cas Classification 
 
The absence of a universal cas gene and its fast evolution (12) has made classification of 
CRISPR/Cas systems difficult. Hence, multi-level classification is adopted, wherein the 
CRISPR/Cas systems are broadly classified into two classes, and further subdivided into six types 
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and 33 subtypes (13–15). The difference between the two classes is that the Class 1 systems have 
multi-subunit effector complexes and in Class 2 systems all functions are performed by a single 
protein effector module (16). Class 1 includes type I, type III and type IV systems. Class 2 includes 
the well-known type II systems (including Cas9 and Cpf1), and much more rare type V and type 
VI systems (14). The classification criteria for classes and types are: a fundamental difference in 
the organization of the effector modules between two classes; unique signature genes for each of 
the types. The classification of subtypes is more complex: for certain subtypes, the signature genes 
are readily defined, while for other subtypes the signature genes are defined through comparison 
of conserved genes and locus organization (17). 
 
CRISPR/Cas9 Structure 
 
 In this review we focus on the most popular Class 2 CRISPR/Cas system with the CRISPR-
associated protein 9 (Cas9) derived from type II-A CRISPR, obtained from Streptococcus 
pyogenes – spCas9. The CRISPR/Cas9 system is a complex composed of single guide RNA 
(sgRNA) and a 160kDa DNA endonuclease enzyme, Cas9 (18), which cuts each strand of double-
stranded DNA at a specific location, through its nuclease domains.  
The sgRNA-bound Cas9 endonuclease binds to a double-stranded DNA (dsDNA) upon 
site-specific recognition of a short trinucleotide Protospacer Adjacent Motif (PAM) within the 
DNA (19). Thereafter, the target DNA (tDNA) strand, which is complementary to the first 20 
nucleotides (-nt) of the sgRNA, forms an RNA-DNA hybrid duplex displacing the non-target DNA 
(ntDNA) strand from the dsDNA (20). The sgRNA (Figure 3) is composed of two noncoding 
RNA components fused together: a CRISPR RNA (crRNA) that confers target specificity to Cas9 
and a transactivating CRISPR RNA (tracrRNA) that can bind to Cas9 (21, 22). The crRNA 
contains the 20-nt long ‘spacer’ or ‘guide’ sequence at the 5'-end that forms the RNA-DNA hybrid, 
and a ‘repeat’ sequence at the 3'-end that forms a duplex with the tracrRNA (18, 23, 24). Since the 
crRNA cannot bind to Cas9 alone, it complexes with the tracrRNA and the resultant RNA:RNA 
duplex fits into Cas9 (22, 25). A sgRNA can be synthetically generated or obtained in vitro or in 
vivo from a DNA template. 
The Cas9 endonuclease (Figure 4) has two lobes: recognition (REC) lobe and nuclease 
(NUC) lobe, connected by an Arginine-rich linker. The REC (residues 56-718) and NUC (residues 
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1-55 and 719-1368) lobes are responsible for association with the sgRNA (7) and cleavage of the 
DNA, respectively. The NUC lobe consists of different domains: RuvC (residues 1-55, 719-765, 
and 919-1099), HNH (residues 780-906), and PAM-interacting (PI) (residues 1100-1368) (7, 26–
28). The RNA-DNA hybrid duplex, with a negatively charged backbone, is accommodated at the 
positively charged groove formed between REC and NUC lobes (7). The unwound ntDNA (u-
ntDNA) strand is proposed to be hosted, before cleavage, at the HNH/RuvC boundary, through 
stabilizing electrostatic interactions between the negatively charged backbone of u-ntDNA and the 
positively charged amino acids of the HNH and RuvC domains (29). The HNH and RuvC domains 
perform site-specific cleavages of the tDNA and ntDNA strands (30), respectively, resulting in a 
double-strand break (DSB), thereby inducing the host DNA repair mechanisms (20). 
 
 
Figure 3: Scheme of the nucleic acid sequence/folding in a CRISPR/Cas9 ternary complex (protein 
+ RNA + DNA) after the Cas9-RNA complex binds to a target DNA. The u-ntDNA strand is 
absent or short in available crystal structures, including PDB ID 4UN3 (27). In this image, it is 
elongated according to an electrostatic interaction hypothesis (31).  The PAM is highlighted in 
yellow and numbering of u-ntDNA strand is shown with nucleotides +1 to +16 upstream of PAM. 
The entire ntDNA strand can be conveniently divided into three segments: PAM duplex, 
nucleotides -1 to -8; PAM-proximal, nucleotides +1 to +8; PAM-distal, nucleotides +12 to +16.  
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Figure 4: Structural representation of the Cas9 endonuclease bound to RNA and DNA, with the 
different protein domains represented in different colors, from PDB ID 4UN3 (27) and with the 
elongated u-ntDNA as in Tangprasertchai et. al. (31). The protein is represented with transparent 
surfaces, the nucleic acids are represented as cartoons, using the visualization software VMD (32).  
 
Molecular Mechanism of CRISPR/Cas9 
 
Crystal structures of SpCas9-sgRNA bound to dsDNA (27, 28) have aided the 
understanding of the molecular mechanism of Cas9-catalyzed DNA cleavage. Site-specific DNA 
recognition and cleavage is achieved after Cas9, in complex with guide RNA (crRNA-tracrRNA 
complex or sgRNA), binds to a target DNA sequence. Thus, as the first step of genome editing by 
CRISPR/Cas9, the Cas9 protein makes extensive interactions with the sgRNA. Specifically, the 
crRNA:tracrRNA duplex and stem loop 1 of the sgRNA (Figure 3) are crucial for Cas9-RNA 
complex formation (33); stem loops 2 and 3 may play a role in increasing catalytic efficiency in 
vivo (5, 7, 33, 34). The Cas9-RNA complex then searches for the complementary target DNA 
sequence, by probing for the PAM (19), highlighted in yellow in Figure 3. The PAM sequence is 
protein-dependent; for SpCas9, it is 5’-NGG-3’, where N can be any DNA base (A, T, G, C). The 
PAM sequence must be found adjacent to the cleavage site in the ntDNA strand. The GG 
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dinucleotide of the PAM in the ntDNA strand is read out via major groove interactions with 
conserved Arginine residues (R1333 and R1335) of the C-terminal domain (CTD in Figure 4) of 
Cas9, also called PAM-interacting (PI) domain. The PI domain of Cas9 also makes contacts with 
the minor groove of the PAM-containing duplex. The residues S1136 and K1107 interact with 
nucleotides of the ntDNA and tDNA strands, respectively, through water-mediated H-bonding. 
Thus, PAM binding is mainly governed by major groove base recognition, but minor groove 
interactions between the PAM and Cas9 orient the tDNA strand for base pairing with sgRNA (27). 
After unwinding of the target DNA duplex, the tDNA strand is stabilized by a “phosphate lock 
loop”, wherein the phosphate group immediately upstream of the PAM is stabilized by amide 
groups of residues K1107-E1108-S1109 (27).  
In a nutshell, local DNA melting is triggered at the PAM-adjacent nucleation site, followed 
by formation of an “R-loop structure” by the RNA-DNA hybrid duplex and the u-ntDNA strand. 
Complementary base pairing between the 20-nt long spacer RNA sequence and the tDNA strand 
is necessary for such target binding specificity and cleavage (18). Upon PAM recognition and 
subsequent R-loop formation, the Cas9 enzyme is activated for DNA cleavage. The HNH and 
RuvC domains cleave the tDNA and ntDNA strands, respectively, at a specific site 3 base pairs 
upstream of the NGG PAM sequence, producing a predominantly blunt-ended DSB (18). In 2016, 
Zuo and Liu argued, on the basis of MD trajectories, that Cas9-catalyzed DNA cleavage can lead 
to 1-bp staggered ends, as opposed to blunt ends (35); while the possibility of obtaining staggered 
ends by Cas9 cleavage is still questionable and needs further evidence, such a cleavage product 
would be conducive to better homologous recombination strategies.  
Another relevant aspect of Cas9 action is that the protein cleaves the target DNA duplex in 
the presence of divalent metal ions, as HNH and RuvC are Mg2+-dependent nuclease domains (36, 
37). The RuvC domain has a typical RNase-H fold structure containing four functionally essential 
residues, D10, E762, H983, and D986, which require a two-metal-ion catalysis mechanism for 
editing (36–38). The HNH domain, on the other hand, has a ββα-metal fold with three catalytic 
residues, D839, H840 and N863, consistent with a one-metal-ion cleavage mechanism (36–38). 
During MD simulations of the CRISPR/Cas9 system in the presence of Mg2+ ions, the tDNA and 
ntDNA strands stabilize near the HNH and RuvC catalytic sites, respectively (30). However, 
currently available force fields for magnesium ions have limitations, which often result in artifacts 
of the coordination sphere of the ion (39). This has been a difficulty in obtaining the mechanistic 
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details of how the catalytic Mg2+ ions meditate the concerted DNA strand cleavage by two 
domains of Cas9. However, this issue has been overcome by employing density functional theory 
(DFT) based quantum-mechanics/molecular-mechanics (QM/MM) hybrid quantum/classical 
simulations (40), which are presented later in this review. 
 
MD Simulations of CRISPR/Cas9 complexes 
 
 The large size and complexity of CRISPR/Cas systems are challenging elements for 
computational studies. The first MD simulations of CRISPR complexes were reported as recently 
as 2015 and addressed the CRISPR/Csy4 complex. In this work, Estarellas et. al. (41) used 
classical all-atom MD simulations in explicit solvent to understand the basic structure and 
dynamics of the binary RNA/Csy4 complex, not including the DNA component. The work 
identified potential catalytic rearrangements of the RNA/Csy4 complex during the simulation time. 
However, the authors also pointed out that the conclusions from MD trajectories could be affected 
by the limitations of available simulation techniques. The limitations were highlighted in the same 
paper by Estarellas and co-workers (41), in order to stimulate in future studies careful analysis and 
a better understanding of the CRISPR/Cas9 system by MD simulations. Important MD limitations 
are connected to the constraints on accessible time scales, the resolution of available crystal 
structures and the accuracy of available force fields; the latter is particularly crucial in molecular 
systems that include an RNA component (41).  
The time-scale limit of MD simulations can be overcome, e.g., by using special hardware 
(Anton by D.W. Shaw Research) (42) or by adopting coarse-grained modeling methods and 
simplified energy functions. In 2016, Wenjun Zheng performed coarse-grained MD simulations 
of a ternary CRISPR/Cas9 complex containing the RNA, DNA, and protein (43). The findings 
were in general agreement with experiments, giving credibility to the report. The work predicted 
few important regions of the protein that can be mutated for improving the specificity of Cas9 and 
also offered new dynamic insights into allosterically triggered structural rearrangements of 
proximal and distal domains of the protein upon sgRNA and DNA binding.  
Regarding the resolution of available crystal structures, cryogenic electron microscopy 
(cryo-EM) can certainly improve the quality of starting MD conformations. At present, there are 
only three entries corresponding to “CRIPSR/Cas9 in complex with sgRNA and DNA” available 
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in the RCSB-PDB database that are obtained from cryo-EM (44). The cryo-EM atomic structure  
has been resolved for binary CRISPR/Cas complexes (45–47). 
The paper by Palermo et. al. (48) should certainly be considered pioneering for the 
computational treatment of CRISPR/Cas9 complexes. The overall process of DNA editing by the 
CRISPR/Cas9 technique was already experimentally established. But the multi-microsecond all-
atom MD simulations by Palermo et. al. revealed the conformational plasticity of the Cas9 
endonuclease and identified the protein conformational changes that occur during nucleic acid 
binding and processing (48). The work specifically pointed towards the role of the ntDNA strand 
in the process of activation of the HNH domain for tDNA strand cleavage. MD simulations were 
carried out for four different systems: (i) apo-Cas9, (ii) a RNA/Cas9 binary complex, (iii) a 
RNA/DNA/Cas9 ternary complex in an intermediate state from PDB ID 4UN3 (27) and (iv) a 
RNA/DNA/Cas9 ternary complex in a pre-catalytic state from PDB ID 5F9R (28). The results of 
these computational experiments showed that the catalytic site H840 of the HNH domain is found 
at a distance of 25 Å from the scissile phosphate of the tDNA strand in the absence of ntDNA, 
incompatible with cleavage activity. The same work reported that instead, in the presence of 
ntDNA, H840 stabilizes at a smaller distance of 15 Å from the scissile phosphate of the tDNA 
strand (Figure 5). It may seem that the distance of 15 Å is still too large for catalytic activity. Still, 
the authors pointed out that in the initial structure the same distance was 18 Å; hence, during the 
MD run the distance decreased to 15 Å in the presence of the ntDNA strand. This investigation 
was followed by the work by Zheng et. al. (43) based on coarse-grained modeling and “essential 
dynamics”. The latter work confirmed the large-scale conformational transitions of Cas9 from the 
unbound form to the binary Cas9-RNA complex and then to the tertiary Cas9-RNA-DNA 
complex. 
Before publication of the work by Palermo et. al. (48), the scientific community mostly 
believed that, since the HNH domain lies between the RuvC II and RuvC III motifs, it should be 
minimally involved in interactions with the rest of the protein. The computational data of Palermo 
et. al. (48), together with experimental data published in 2016 by Slaymaker et. al. (29), confirmed 
the importance of the HNH domain in the concerted editing mechanism. Moreover, according to 
Slaymaker et. al. (29), the u-ntDNA strand can be accommodated at the HNH/RuvC interface, 
through stabilizing electrostatic interactions between the negatively charged backbone of u-ntDNA 
and the positively charged amino acids at the HNH/RuvC interface. This evidence was exploited 
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to build a model CRISPR/Cas9 ternary complex with a significantly long u-ntDNA strand (31), 
which was reported in 2017 and is discussed later in this review.  
 
 
Figure 5: Representative structures from the MD trajectory obtained starting from the ternary 
complex in PDB ID 5F9R, (a) without the ntDNA strand (w/o nt-DNA) and (b) with the ntDNA 
strand. In the absence of the ntDNA strand, the catalytic H840 moves to a distance of ∼25 Å from 
the scissile phosphate P-3 on the tDNA strand, being initially at ~18 Å distance. In the presence 
of the ntDNA strand, H840 approaches P-3 at ∼15 Å distance. From Ref. (48), with permission.  
 
As observed in the crystal structure (28), the HNH and RuvC domains are linked by hinge 
regions LI (residues 765-780) and LII (residues 906-918) (Figure 4) with an extended network of 
H-bonds. The LI-ntDNA contacts observed in the crystal structure are well conserved during the 
MD simulations (48). More importantly, the K913 residue of the LII loop forms an H-bond with a 
nucleotide of the ntDNA strand, which is stable over the time scale of ~0.75 ns during the MD run. 
This conformation is suggested to stabilize the H840 catalytic site of HNH domain at a distance 
of ~15 Å from the scissile phosphate on the tDNA strand, and cleavage of the tDNA strand by 
H840 follows. The communication between the RuvC domain and the ntDNA strand that 
influences the HNH catalytic domain positioning has been termed “crosstalk” between HNH and 
RuvC domains, which is dependent on the interactions between the hinge region and ntDNA strand 
(48). Thus, we now believe that the arrangement of the u-ntDNA strand in the complex is crucial 
for DNA editing. Another important aspect that was described in the same work (48) is that, in 
order for the ntDNA to bind the RuvC domain, it is important for the HNH domain to reposition, 
which is possible because the HNH domain has an inherent conformational plasticity, as revealed 
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from comparative MD simulations of CRISPR/Cas9 ternary complexes in pre-catalytic (PDB ID 
5F9R) and presumably post-catalytic (PDB ID 4UN3) states. 
The work by Palermo et. al. published in 2017 in the Proceedings of the National Academy 
of Sciences USA (30) is devoted to the recognition and binding of the RNA by Cas9, poorly 
addressed previously. The computational results highlighted two significant facts: (i) 
conformational changes occur during CRISPR/Cas9 activation, specifically characterizing the 
conformational transition of Cas9 from its apo form to the RNA-bound form, thereby suggesting 
a mechanism for RNA binding within the protein; and (ii) crucial conformational changes in the 
HNH domain lead to a catalytically competent Cas9 conformation ready for cleaving the DNA. A 
dramatic conformational change was observed between the apo and RNA-bound structures of Cas9 
by targeted MD (TMD) simulations. The apo Cas9 was obtained by removing the RNA from the 
RNA/Cas9 complex. The TMD trajectories revealed conformational rearrangements that mainly 
involve the REC lobe of Cas9. The REC lobe was observed to open up with respect to the 
comparatively stable nuclease lobe. During this process, the arginine rich helix was exposed into 
the solvent, forming a positively charged cavity that can accommodate the RNA. Single-molecule 
Foster Resonance Energy Transfer (FRET) experiments could reveal insights into the mechanism 
of RNA recognition at the atomistic level. In the simulations, the three regions RECI, RECII and 
RECIII that form the REC lobe were observed to move in different directions. In particular, the 
RECI region, together with the arginine rich helix, moves in the opposite direction as compared to 
the RECIII region. These observations are consistent with previous experimental (49) and 
computational studies (43, 48), suggesting that protein domains move concertedly in different 
directions for nucleic acid recognition. Palermo et. al. (30) compared the Cas9 conformational 
changes to an “earth and moon” model (Figure 6), where each individual protein domain rotates 
around the main protein axis (q) and itself (f). The extent of rotation of RECIII (theta angle of ∼60° with respect to the protein and phi angle of ∼90° with respect to itself) was much larger than 
the rotation of RECII.  
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The MD trajectories 
indicate that the high 
flexibility of the HNH domain 
controls the DNA cleavage, 
which is in agreement with 
biochemical evidences (50). 
As already mentioned, this 
flexibility depends on the 
conformational dynamics of 
the linker region between the 
HNH and RuvC domains. 
Further evidence for the role of 
linkers is provided by Palermo 
et. al. (30) by TMD simulations and confirmed by single-molecule FRET experiments by Dagdas 
et al. (51). In a nutshell, it is proposed that collaborative interactions between LI/LII linkers and 
DNA cause the activation of RuvC and HNH domains for concerted cleavage of the DNA strands. 
The active and inactive states of HNH were well distinguished by Gaussian-accelerated 
MD (GaMD) simulations (30), which reveal that the transition of the HNH domain from the 
inactive to the active state should involve a critical step, namely binding of dsDNA. This evidence 
was supported by the TMD simulations of the HNH transition (30), suggesting that HNH 
repositioning might occur during DNA unwinding, leading to the speculation that the high 
flexibility of the HNH domain might somehow facilitate unwinding of dsDNA and formation of 
R-loop structure (48–50). Overall, by using equilibrium MD, GaMD and TMD simulations, the 
conformational dynamics involved in RNA recognition, DNA unwinding and DNA cleavage by 
Cas9 has been substantially explained.  
The first step in CRISPR/Cas9 genome editing is, however, recognition of the PAM motif: 
the mechanism through which PAM binding activates Cas9 for DNA cleavage at spatially distant 
sites still needs understanding. Palermo et. al. (52) provided evidence of a PAM-induced allosteric 
mechanism in CRISPR/Cas9 by MD sampling over ~13µs, employing simulation conditions 
tailored for DNA/RNA endonucleases, for two different systems: Cas9 with guide RNA and its 
matching DNA containing a 5′ -TGG-3′  PAM sequence (referred as Cas9 with PAM: Cas9-
Figure 6: Schematic view of an earth and moon model of the 
system, where the θ and φ angles describe the rotation of each 
individual protein domain (here shown for HNH) with respect to 
the protein (θ) and itself (φ). The graphs report the time 
evolution of the θ (“earth”) and φ (“moon”) angles for the 
regions RECI-III and for the R-rich helix, along targeted MD. 
Adapted from Ref. (30), with permission. 
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wPAM, from PDB ID 4UN3 (27)),  and its analogue, crystallized without the PAM segment (Cas9-
w/oPAM, from PDB ID 4OO8 (7)). The work concluded that PAM functions as an allosteric 
effector that triggers interdependent conformational dynamics of the HNH and RuvC domains, 
required for concerted cleavage of DNA strands. A similar allosteric communication was observed 
using intramolecular FRET experiments by Sternberg et. al. (50).   
 Principal modes of motion obtained from MD simulations of Cas9-wPAM and Cas9-
w/oPAM revealed an “open-to-close” conformational transition for Cas9, which is necessary for 
nucleic acid binding (30, 48). In the presence of PAM, the correlated residues exhibit higher 
correlation strength necessary for allosteric signaling, as compared to the correlation strength in 
the absence of PAM. The PAM-induced conformational transition increases the strength of 
correlated motions between RuvC and HNH domains, inducing a stronger communication channel 
between these two nuclease domains. Allosteric signaling is triggered by electrostatic interactions 
between charged amino acids (16). Palermo et. al. specifically pointed out that Q771 and E584 
interact with K775 and R905, respectively, forming essential edges of the allosteric pathway. 
These interactions connect HNH to RuvC and the α-helical lobe via the linkers LI and LII, which 
effectively function as “allosteric transducers” (28, 50). The optimal path for information flow was 
identified through the LI loop, via residues K772 and T770. Very recently, the allosteric 
mechanism of information transfer across the HNH domain has been investigated by East et. al. 
(53) using a combination of solution NMR experiments and MD simulations. The complete 
allosteric pathway spans the HNH domain from the region interfacing the RuvC domain up to the 
RECII region. The DNA binding signal propagates across the recognition lobe and the nuclease 
domains (HNH and RuvC), for concerted cleavage of the t-DNA and nt-DNA strands.  
 Molecular simulations so far have significantly contributed to understanding Cas9 structure 
and function, as summarized above. Yet, little is known about the catalytically active states of 
Cas9 HNH and RuvC domains. The first model of the fully catalytic CRISPR/Cas9 was reported 
by Palermo et. al. in 2017 in the Proceedings of the National Academy of Sciences USA (30), 
already cited above. In 2016, Zuo and Liu reported the catalytically competent state of the RuvC 
domain by MD simulations (35), but the HNH conformations were elusive. In 2017 (54), the same 
authors reported the missing link to decipher how the HNH domain transitions from the pre-
catalytic state to the catalytic state. They employed two distinct sampling techniques: biased 
targeted-MD (tMD) and unbiased ensemble conventional MD (cMDens). They obtained a cross-
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validated catalytically active state of the Cas9 HNH domain primed for cutting the tDNA strand. 
The SpCas9 crystal structures corresponding to different binding stages (6, 7, 27, 28, 49) can be 
used to understand the conformational activation pathway of the HNH domain of Cas9 (Figure 7). 
Zuo and Liu found that Mg2+ ions are indispensable for the formation and stability of the catalytic 
state of the HNH domain, which is in accordance with experimental reports by Jinek et. al. (4) and 
Dagdas et. al. (51). In addition, the results by Zuo and Liu suggest that Mg2+ ions also act as 
facilitators and stabilizers of the functional conformational state. 
 
 
Understanding the catalytic mechanism involved in accurate editing by CRISPR/Cas9 is 
particularly important, but it has been poorly addressed so far, due to uncertainties in the available 
Figure 7: Conformational activation pathway of Cas9 HNH nuclease domain. The HNH 
domain and flanking linker regions (i.e. L1 and L2) are highlighted in magenta and yellow, 
respectively. The PAM is colored dark red and the three putative catalytic residues of HNH 
domain are represented as blue spheres. From Ref. (54) with permission. 
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crystal structures of Cas9. Recently, Yoon et. al. (55) attempted to analyze the catalytic mechanism 
and the energetics for the activation of Cas9, by using the empirical valence-bond (EVB) method. 
However, the investigation was based on a Cas9 analogous protein, the endonuclease VII and the 
conclusions were made based on the structural similarity between Cas9 and endonuclease VII. 
Yoon and co-workers specifically looked for the catalytic roles of two positive residues K848 and 
K855 in the HNH domain. They found that the catalytic state most likely involves a structure 
where K848 comes close to the scissile phosphate of tDNA strand. 
Little is known about the catalytic state of the nuclease domain in CRISPR/Cas9 and even 
less is known about the location and binding of divalent metal ions within the RuvC nuclease 
domain active site, necessary for cleavage of nt-DNA strand. Zuo and Liu in 2016 (35) attempted 
to understand the metal-aided cleavage mechanism by classical MD simulations. The identified 
catalytic site shows that the pro-Rp and pro-Sp oxygen atoms of the scissile phosphate coordinate 
the MgA and MgB ions, respectively (Figure 8a). This is unlikely to give rise to phosphodiester 
bond cleavage, which instead would require only the pro-Sp oxygen of the scissile phosphate to 
jointly coordinate with the two 
Mg2+ ions, enabling an in-line SN2 
nucleophilic attack. This is a well-
known requirement for the two-
metal aided catalysis (36, 56). 
Using QM/MM simulations with 
the quantum mechanical portion of 
the system described at the DFT 
level, Palermo and co-authors 
revealed in 2019 a new geometry 
for the active site with joint coordination of the two Mg2+ ions by the pro-Sp oxygen of the scissile 
phosphate (Figure 8b) (40). This agrees well with the requirements for the catalysis, as it favors 
an in-line SN2-like nucleophilic attack. Thus, it is likely that the active site geometry obtained by 
Zuo and Liu via classical MD might have been affected by the limitations of the classical force 
field for Mg2+ ions and the same limitation may be responsible for “staggered cleavage”.  
The computational works discussed above were dedicated to understanding the structure, 
dynamics and function of the NUC lobe of Cas9 (or other analogous protein), specifically the 
Figure 8: The active site geometry of RuvC domain as 
obtained from (a) classical MD by Zuo and Liu in 2016 
and (b) QM/MM by Palermo et. al. in 2019. From Ref 35 
and Ref 40, respectively, with permissions.  
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nuclease domains HNH and RuvC. Other parts of the protein may participate in structural 
transformations to attain cleavage-prone conformations.  A recently published work by Palermo 
et. al. (57), based on 16 µs  of unbiased MD simulations performed using Anton-2, revealed that 
the conformational change in the HNH domain during DNA cleavage is accompanied by a 
remarkable structural remodeling of the REC lobe. The conformational changes in the REC lobe 
indicate that the RECI, RECII and RECIII domains ‘sense’ nucleic acids, ‘regulate’ the HNH 
conformational transition and ‘lock’ the HNH domain at the cleavage site, leading to the formation 
of a catalytically active CRISPR/Cas9 complex. Thus, a subtle interplay between the REC and 
NUC lobes is observed upon activation, ultimately ensuring catalytic competence. 
The CRISPR/Cas9 approach has been exploited for efficient genome editing in a wide 
variety of organisms. However, the method exhibits a major undesired effect: it results in unwanted 
editing at off-target sites that are similar to on-target DNA sequences (58, 59). It is important to 
make progress towards eliminating such off-target effects on a genome-wide scale. Within the 
framework of the hypothesis proposed for Cas9-sgRNA (29, 58), the structural information 
obtained from all previous MD investigations has been exploited to rationally design Cas9 variants 
with improved specificity. Palermo and coworkers (60) devoted attention towards off-target 
cleavage. The authors decipher the mechanism of off-target binding at the molecular level, using 
GaMD simulations. They conclude that base pair mismatches in the target DNA at specific distal 
sites with respect to the PAM induce an extended opening of the RNA-DNA hybrid duplex, which 
leads to newly discovered interactions between the unwound nucleic acids and the protein 
counterpart. This work, which focuses on interactions between DNA and the protein HNH domain, 
poses the foundations for designing novel and more specific Cas9 variants. Based on the structural 
information obtained from their MD simulations, Zuo and Liu suggested more than a dozen 
potential mutation sites in the NUC lobe of Cas9 for generating Cas9 variants with improved 
specificity (54). On the other hand, Palermo et. al. (57) focused on the REC lobe to control off-
target effects.  
 In addition to dynamics of wild-type SpCas9, the dynamics of Cas9 mutants have also been 
explored using MD simulations for understanding off-target effects. Zheng et. al. (61) selected 
four mutants: N497A, R661A, Q695A and Q926A (referred to as nrqqCas9). This choice was 
based on the experimental work by Kleinstiver et. al. (58), that show ability to decrease all, or 
nearly all, genome-wide off-target effects. The work by Zheng and co-workers (56) provided the 
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much-needed atomistic explanation for the lowering of off-target effects accompanied by lowering 
of on-target cleavage efficiency of nrqqCas9. The results indicated that the mutations cause a loss 
in the electrostatic interactions between Cas9 and the RNA-DNA hybrid duplex, especially in the 
PAM distal segment. The nrqqCas9 systems adopt slightly open conformation with fewer 
interactions between HNH and RuvC domains, with consequently reduced efficiency for on-target 
and off-target DNA cleavage. 
The issue of specificity is also currently 
addressed in our group, by MD simulations of 
CRISPR/Cas9 complexes with protein mutations at 
the HNH/RuvC boundary. Our work is inspired by 
the suggestion, based on experimental data (29), 
that attractive electrostatic interactions between 
positive protein residues at this boundary and the 
negative backbone of the u-ntDNA strand keep the 
u-ntDNA strand unwounded (Figure 9), thus 
preventing the re-formation of the DNA duplex and 
keeping the system ready for cleavage. Protein 
mutations from charged to neutral amino acids can 
weaken the protein-ntDNA attraction and induce 
the duplex DNA re-hybridization if the RNA:tDNA 
duplex is not strong enough, e.g. in the case of 
imperfect complementarity. We have already positively tested this model (Figure 10) using a 1.5 
µs MD trajectory of a modeled structure derived from PDB ID 4UN3, with an elongated ntDNA 
strand accommodated at the HNH/RuvC positive patch (31). We validated this model by a 
combination of MD and electron paramagnetic (EPR) measurements of spin-labeled 
CRISPR/Cas9 ternary complexes, with nitroxide spin labels on the DNA backbone. EPR measured 
distances between chosen DNA sites resulted in agreement with distances between the same sites 
extracted from the MD trajectory with nitroxides added through the software NASNOX (62), 
which accounts for all sterically allowed rotamers. 
Until now, MD simulations have been mostly utilized to characterize the interactions 
between different segments of CRISPR/Cas9: Cas9-tDNA, Cas9-ntDNA, PAM-DNA, etc. 
Figure 9: Scheme of various competitive 
interactions in the system.protein-ntDNA, t-
DNA-ntDNA, tDNA-RNA. If the protein-
ntDNA interaction strength is decreased by 
mutating charged Cas9 residues to neutral 
residues, there will be a driving force 
towards DNA duplex re-hybridization, 
unless the hybrid RNA:tDNA duplex is very 
strong, which is the case for perfect 
complementarity.  
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Attention has been mostly focused on the HNH and RuvC domains, as these compose the catalytic 
region and contain the nuclease active site, with very little work on the REC lobe. We anticipate 
the need for large amounts of experimental and theoretical/computational work to explore other 
parts of the protein, which may play crucial allosteric roles in nucleic acid recognition and 
cleavage. More extensive comprehension of structural design will eventually enable scientists to 
tailor specific Cas9 variants with no off-target effects. 
 
 
Limitations and Future Directions 
 
 The nuclease activity of Cas9 can be triggered even when there is imperfect 
complementarity between the sgRNA and an off-target genomic site, particularly if mismatches 
are distal to PAM (27, 59, 63). These off-target effects are serious limitations to the practical use 
of CRISPR/Cas in genetic therapies, agriculture and other potential applications with societal 
impact. Anders et. al. (27). crystallized two Cas9/sgRNA/DNA complexes, where the DNA 
contains mismatches to the guide RNA. They revealed that, even in the absence of full 20-nt 
complementary base pairing between DNA and RNA, target DNA binding by Cas9/RNA results 
Figure 10: Left: scheme of the experimental system for EPR measurements. Center: Measured 
distance profiles for selected DNA sites. Right: simulated structure, with the elongated ntDNA 
in black and the sites for distance calculations visualized as spheres. From Ref (31) with 
permission. 
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in local strand separation immediately upstream of the PAM, thereby leading to cleavage of 
DNA strands in undesired conditions. Such off-target activities are prominent when the 
mismatches are distal to PAM. Slaymaker et. al. (29) reported a structure-guided protein 
engineering method that promises to improve the specificity of the CRISPR technology, at least 
when the endonuclease is SpCas9. It is hypothesized that neutralizing the positively charged 
residues at the interface between HNH and RuvC domains, where the u-ntDNA strand is hosted, 
could weaken the ntDNA strand binding to protein (Figure 9). This would encourage re-
hydridization between the tDNA and ntDNA strands, causing “R-loop collapse”. Hence, a more 
stringent Watson-Crick base pairing between guide RNA and target DNA would be necessary 
to prevent the R-loop collapse. Slaymaker et. al. (29) initially generated thirty-one SpCas9 
mutants replacing charged amino acids at the HNH/RuvC interface with alanine. The top five 
specificity conferring mutants were R780A, K810A, K848A, K855A and H982A. We are 
currently performing µs-long MD simulations to investigate the structural and dynamical basis 
of this intriguing hypothesis. Specifically, we are addressing CRISPR/Cas9 ternary complexes 
with wild-type Cas9 and three Cas9 mutants: K855A, H982A and a combination 
K855A+H982A. We use the system derived from PDB ID 4UN3, with an elongated u-ntDNA 
strand (Figure 9) (31) and modeled missing Cas9 residues. Preliminary results (64), obtained 
by the comparison between complexes with wild-type and mutated Cas9 complexes, yield 
structural insights into the active DNA-bound state of the RuvC domain, highlighting motions 
that are consistent with the competing electrostatic interactions as illustrated in Figure 9. Our 
preliminary results concur with the hypothesis that protein mutations can be exploited to 
produce more specific CRISPR/Cas9 variants. 
A sgRNA, formed by crRNA and tracrRNA, and the PAM region in the DNA, are essential 
for Cas9-mediated dsDNA cleavage in the presence of Mg2+ ions. Sundaresan et. al.  (65), 
however, demonstrated that FnoCas9 and FnoCas12a possess RNA-independent, non-sequence-
specific cleavage activities on dsDNA targets in the presence of Mn2+. This finding emphasizes 
the need for further characterization of CRISPR systems towards the development of applications 
to living genomes.  
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